Moleculin Biotech logo

Moleculin Biotech

MBRX | NASDAQ
Chart Builder DCF Calculator
$7.14
-$0.73 (-9.28%)
At close: Nov 16, 2026, 4:00 PM ET
$7.46
+$0.32 (+4.48%)
After-hours: Nov 16, 2026, 7:30 PM ET
-9.28%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
30.3
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #788/1021 (Top 77%)

Key Statistics

Market Data

Market Cap $7.28M
1D Range
7.03 7.75
52W Range
5.30 219.20

Valuation (TTM)

PE -0.61
PB 0.50
EV/EBITDA -0.01

Valuation (NTM)

Forward PE N/A
Forward PEG 0.01
Price Target $3.00
Loading financial charts...

Profile

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary invest...

Sector Healthcare
Industry Biotechnology
Employees 17
IPO Date Jun 2, 2016
Fiscal Year January - December

Latest News

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

28 days ago · globenewswire.com

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Moleculin Announces Reverse Stock Split

1 month ago · globenewswire.com

Moleculin Announces Reverse Stock Split
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

1 month ago · globenewswire.com

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

2 months ago · globenewswire.com

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

2 months ago · globenewswire.com

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

2 months ago · globenewswire.com

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

2 months ago · globenewswire.com

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

2 months ago · globenewswire.com

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

2 months ago · globenewswire.com

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$3.00
Downside
-57.98%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.